Tebentafusp for treating advanced uveal melanoma (TA1027)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2025
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 December 2024
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 October 2024
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 August 2008
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 27 November 2013
Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 20 May 2024Published: 22 May 2013
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) (TA960)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) (TA941)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Ranibizumab for treating diabetic macular oedema (TA274)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2023Published: 27 February 2013
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 September 2022
Brolucizumab for treating diabetic macular oedema (TA820)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2022
Faricimab for treating diabetic macular oedema (TA799)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Faricimab for treating wet age-related macular degeneration (TA800)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Brolucizumab for treating wet age-related macular degeneration (TA672)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 July 2019
Aflibercept for treating choroidal neovascularisation (TA486)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2017
Holoclar for treating limbal stem cell deficiency after eye burns (TA467)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 August 2017
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 July 2017
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2015
Aflibercept for treating diabetic macular oedema (TA346)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 July 2015
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 February 2014
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2011
Teprotumumab for treating thyroid eye disease [ID6432]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 August 2025
Glaucoma - lerdelimumab (CAT-152) [ID383]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Timrepigene emparvovec for treating choroideremia [ID3916]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC